{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:10:14Z","timestamp":1739405414991,"version":"3.37.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.2515\/therapie\/2009033","type":"journal-article","created":{"date-parts":[[2009,10,29]],"date-time":"2009-10-29T10:49:42Z","timestamp":1256813382000},"page":"321-323","source":"Crossref","is-referenced-by-count":3,"title":["\u00c9pilepsie myoclonique juv\u00e9nile avec \u00e9tats de mal myocloniques r\u00e9currents : efficacit\u00e9 du valproate"],"prefix":"10.1016","volume":"64","author":[{"given":"Arielle","family":"Crespel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reana","family":"Velizarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Genton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"G\u00e9lisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2009033_bb0005","series-title":"Les syndromes \u00e9pileptiques de l\u2019enfant et de l\u2019adolescent","first-page":"367","article-title":"\u00c9pilepsie myoclonique juv\u00e9nile","author":"Thomas","year":"2005"},{"key":"10.2515\/therapie\/2009033_bb0010","first-page":"97","article-title":"Aspects g\u00e9n\u00e9tiques de l\u2019\u00e9pilepsie myoclonique juv\u00e9nile","volume":"13","author":"G\u00e9lisse","year":"2001","journal-title":"Epilepsies"},{"key":"10.2515\/therapie\/2009033_bb0015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1528-1157.1988.tb03718.x","article-title":"Juvenile myoclonic epilepsy: a study in Saudi Arabia","volume":"29","author":"Obeid","year":"1988","journal-title":"Epilepsia"},{"key":"10.2515\/therapie\/2009033_bb0020","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1034\/j.1600-0404.2000.102003188.x","article-title":"Structural brain lesions do not influence the prognosis of juvenile myoclonic epilepsy","volume":"102","author":"G\u00e9lisse","year":"2000","journal-title":"Acta Neurol Scand"},{"key":"10.2515\/therapie\/2009033_bb0025","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"10.2515\/therapie\/2009033_bb0030","first-page":"708","article-title":"Treatment of juvenile myoclonic epilepsy with lowdose sodium valproate","volume":"152","author":"De Toffol","year":"1996","journal-title":"Rev Neurol (Paris)"},{"key":"10.2515\/therapie\/2009033_bb0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2515\/therapie\/2008069","article-title":"Les m\u00e9dicaments anti\u00e9pileptiques","volume":"63","author":"G\u00e9lisse","year":"2008","journal-title":"Therapie"},{"key":"10.2515\/therapie\/2009033_bb0040","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1212\/WNL.55.11.1757","article-title":"Exacerbation of juvenile myoclonic epilepsy with lamotrigine","volume":"55","author":"Biraben","year":"2000","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2009033_bb0045","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/01.wnl.0000174517.21383.36","article-title":"Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies","volume":"65","author":"Crespel","year":"2005","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2009033_bb0050","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1001\/archneur.62.11.1705","article-title":"Topiramate in patients with juvenile myoclonic epilepsy","volume":"62","author":"Biton","year":"2005","journal-title":"Arch Neurol"},{"key":"10.2515\/therapie\/2009033_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1684\/j.1950-6945.2004.tb00075.x","article-title":"Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy","volume":"6","author":"Kothare","year":"2004","journal-title":"Epileptic Disord"},{"key":"10.2515\/therapie\/2009033_bb0060","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"10.2515\/therapie\/2009033_bb0065","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2006.05.013","article-title":"Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy","volume":"71","author":"Specchio","year":"2006","journal-title":"Epilepsy Res"},{"key":"10.2515\/therapie\/2009033_bb0070","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1136\/jnnp.70.2.240","article-title":"Clinical factors of drug resistance in juvenile myoclonic epilepsy","volume":"70","author":"G\u00e9lisse","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.2515\/therapie\/2009033_bb0075","first-page":"75","article-title":"The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies","volume":"75","author":"Nicolson","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716306278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716306278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T23:51:53Z","timestamp":1739404313000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716306278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["S0040595716306278"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2009033","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}